PRANA's PBT2 Reverses the Loss of Synaptic Activity in Neurons

Prana Biotechnology (NASDAQ: PRAN) today announced that scientists from Merz Pharmaceuticals GmbH and the Max Planck Institute presented data showing that Prana's PBT2 improves synaptic activity in neurons needed for memory. The scientists presented their data at The Society for Neuroscience meeting in Washington D.C. in a poster titled "Aggregation inhibitors reverse β-amyloid (Aβ)-induced inhibition of long term potentiation in murine hippocampal slices". The experiments reported that PBT2 was able to prevent synapatic toxicity or loss of signal conductivity, caused by the formation of toxic Aβ oligomers. The data indicates that it may be most beneficial for neuroprotective agents such as PBT2, that can interrupt Aβ self-assembly into aggregates, to be administered to early stage patients to best maintain synaptic plasticity and function as an effective treatment for Alzheimer's Disease (AD).